MTURN

Across TCGA pan-cancer cohorts, MTURN mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTURN data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTURN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MTURN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where MTURN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.910	0.643	<.001	74	view →
HNSC	OS	Median	All	0.934	1.000	.003	46	view →
CCRCC	OS	Quartile	All	0.922	0.738	.009	15	view →
LSCC	DFS	Median	All	0.874	1.000	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTURN–PDAC (DFS)

Open the PDAC breakdown →